For more information on porphyria, contact the American Porphyria Foundation at www.porphyria foundation.com or at 1-866-APF-3635. Imagine having a rare and sometimes fatal disease that causes ...

Patients with symptomatic acute hepatic porphyria were found to be at greater risk of accessing long-term sick leave and disability pension compared with the general population, but were not shown to ...

Myelodysplastic syndrome occurs occasionally after high-dose chemotherapy with autologous stem cell transplantation.1 2 Porphyria cutanea tarda is an uncommon disorder characterized by vesicular ...

Acute porphyria is a group of uncommon diseases that can cause severe, potentially life-threatening attacks of abdominal pain, nausea, vomiting and paralysis. Liver transplantation is currently the ...

Please provide your email address to receive an email when new articles are posted on . Clinicians are hoping an RNA interference therapeutic targeting aminolevulinic acid synthase 1, known as ...

Patients with porphyria cutanea tarda have more cutaneous lesions in summer than in winter, but only after prolonged and chronic exposure to light. Some patients excrete red, fluorescent urine during ...

Congenital erythropoietic porphyria, a rare autosomal recessive disorder of heme biosynthesis, results from markedly deficient uroporphyrinogen III synthase activity. 1,2 Data regarding pregnancy in ...

Scientists have identified variations in a transport protein that help explain symptom severity in porphyria patients and suggest possible treatment strategies. An international research team has ...

What is the appropriate treatment for a patient with acute intermittent porphyria and hepatitis B (e-antigen negative) with a normal alanine transaminase and a hepatitis B virus viral load of 45,000 ...

− Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups – − ...